PuSH - HMGU Publikationen https://push-zb.helmholtz-munich.de PuSH - Publikationen-Server des Helmholtz Zentrums München de-de <![CDATA[Burström, K.* et al. Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states. Pharmacoeconomics 38, 839-856 (2020)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=58879&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=58879&la=de Wed, 22 Apr 2020 00:00:00 +0000 <![CDATA[Kähm, K. ; Laxy, M. ; Schneider, U.* & Holle, R. Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: A large claims-based in Germany. Pharmacoeconomics 37, 63-74 (2019)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=54225&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=54225&la=de Wed, 05 Sep 2018 00:00:00 +0000 <![CDATA[Laxy, M. et al. Performance of the UKPDS outcomes model 2 for predicting death and cardiovascular events in patients with type 2 diabetes mellitus from a German Population-Based Cohort. Pharmacoeconomics 37, 1485-1494 (2019)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=56648&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=56648&la=de Thu, 01 Aug 2019 00:00:00 +0000 <![CDATA[Stollenwerk, B. et al. A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. Pharmacoeconomics 36, 603-612 (2018)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=53083&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=53083&la=de Mon, 05 Mar 2018 00:00:00 +0000 <![CDATA[Iglesias, C.P.* ; Thompson, A.* ; Rogowski, W.H. & Payne, K.* Reporting guidelines for the use of expert judgement in model-based economic evaluations. Pharmacoeconomics 34, 1161-1172 (2016)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=49024&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=49024&la=de Sat, 09 Jul 2016 00:00:00 +0000 <![CDATA[Mensch, A.* ; Stock, S.* ; Stollenwerk, B. & Müller, D.* Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics 33, 271-283 (2015)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=42842&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=42842&la=de Thu, 27 Nov 2014 00:00:00 +0000 <![CDATA[Rogowski, W.H. et al. Concepts of 'personalization' in personalized medicine: Implications for economic evaluation. Pharmacoeconomics 33, 49-59 (2015)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=32370&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=32370&la=de Fri, 26 Sep 2014 00:00:00 +0000 <![CDATA[Schremser, K. et al. Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33, 1215-1228 (2015)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=45335&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=45335&la=de Fri, 19 Jun 2015 00:00:00 +0000 <![CDATA[Hatz, M.H.M. ; Schremser, K. & Rogowski, W.H. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics 32, 443-455 (2014)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=30698&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=30698&la=de Tue, 04 Mar 2014 00:00:00 +0000 <![CDATA[Hatz, M.H.M. ; Leidl, R. ; Yates, N.A. & Stollenwerk, B. A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Pharmacoeconomics 32, 377-393 (2014)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=30577&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=30577&la=de Mon, 17 Feb 2014 00:00:00 +0000 <![CDATA[Heimeshoff, M.* ; Hollmeyer, H.* ; Schreyögg, J. ; Tiemann, O. & Staab, D.* Cost of illness of cystic fibrosis in Germany: Results from a large cystic fibrosis centre. Pharmacoeconomics 30, 763-777 (2012)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=10415&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=10415&la=de Thu, 04 Oct 2012 00:00:00 +0000 <![CDATA[Menn, P. ; Leidl, R. & Holle, R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics 30, 825-840 (2012)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=8354&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=8354&la=de Tue, 21 Aug 2012 00:00:00 +0000 <![CDATA[Blankart, C.R.B. ; Stargardt, T. & Schreyögg, J. Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics 29, 63-82 (2011)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4697&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4697&la=de Thu, 26 May 2011 00:00:00 +0000 <![CDATA[Leidl, R. & Reitmeir, P. A value set for the EQ-5D based on experienced health states: Development and testing for the German population. Pharmacoeconomics 29, 521-534 (2011)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=6430&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=6430&la=de Tue, 02 Aug 2011 00:00:00 +0000 <![CDATA[Menn, P. & Holle, R. Comparing three software tools for implementing markov models for health economic evaluations. Pharmacoeconomics 27, 745-753 (2009)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=2257&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=2257&la=de Thu, 31 Dec 2009 00:00:00 +0000 <![CDATA[Kreck, S.* et al. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: Cost-utility analysis using a Markov model. Pharmacoeconomics 26, 311-328 (2008)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=2657&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=2657&la=de Thu, 20 Nov 2008 00:00:00 +0000 <![CDATA[Bos, J.M.* et al. Combination vaccine against invasive meningococcal B and pneumococcal infections: Potential epidemiological and economic impact in The Netherlands. Pharmacoeconomics 24, 141-153 (2006)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4708&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4708&la=de Mon, 24 Apr 2006 00:00:00 +0000 <![CDATA[Stark, R.G. ; König, H.-H.* & Leidl, R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 24, 797-814 (2006)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4978&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4978&la=de Thu, 16 Nov 2006 00:00:00 +0000 <![CDATA[Welte, R. ; Trotter, C.* ; Edmunds, W.* ; Postma, M.J.* & Beutels, P.* The Role of Economic Evaluation in Vaccine Decision Making. Pharmacoeconomics 23, 855-874 (2005)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4849&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=4849&la=de Tue, 20 Dec 2005 00:00:00 +0000 <![CDATA[Welte, R. ; Feenstra, T.* ; Jager, H.* & Leidl, R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 22, 857-876 (2004)]]> https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=3802&la=de https://push-zb.helmholtz-munich.de/frontdoor.php?source_opus=3802&la=de Fri, 10 Sep 2004 00:00:00 +0000